Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Cantor Fitzgerald
Chinese Patent Office
US Army

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 3,686,412

« Back to Dashboard

Summary for Patent: 3,686,412

Abstract:Pharmaceutical compositions comprising a pharmaceutical carrier and a bis-chromonyl compound of the formula ##SPC1## And therapeutically acceptable salts, esters and amides thereof, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each selected from the group consisting of hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, hydroxyloweralkyl, haloloweralkyl, hydroxyloweralkoxy, loweralkoxyloweralkoxy and carboxyloweralkoxy; and X is selected from the group consisting of saturated and unsaturated, straight and branched hydrocarbon chains which may be interrupted by a member selected from the group consisting of benzene rings, dioxanyl, oxygen atoms and carbonyl groups, and which may be substituted by a member selected from the group consisting of halogen atoms, hydroxy groups and lower alkoxy groups are active to inhibit antigen-antibody reaction.
Inventor(s): Fitzmaurice; Colin (Holmes Chapel, EN), Lee; Thomas Brian (Holmes Chapel, EN)
Application Number:05/077,711
Patent Claim Types:
see list of patent claims
Composition; Formulation; Delivery; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 3,686,412

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom12626/65Mar 25, 1965
United Kingdom52414/65Dec 9, 1965

International Patent Family for Patent: 3,686,412

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria269138► Subscribe
Belgium678175► Subscribe
Switzerland476720► Subscribe
Switzerland481912► Subscribe
Switzerland484895► Subscribe
Switzerland486445► Subscribe
Switzerland488688► Subscribe
Switzerland495978► Subscribe
Switzerland504432► Subscribe
Germany1543579► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Queensland Health
US Army
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: